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Rapport de synthèse 
Buts de la revue: 
Les Médulloblastomes sont des tumeurs rares chez l'adulte. Le traitement habituel comprend 
une radiothérapie de tout l'axe cranio-spinal avec ou sans chimiothérapie. Beaucoup 
d'efforts sont actuellement entrepris pour mieux comprendre la biologie tumorale, afin de 
mieux stratifier les patients en différents groupes à risques et de les traiter en fonction. Cette · 
revue discute les nouveaux facteurs de risques cliniques et moléculaires qui peuvent aider à 
optimiser le traitement des patients adultes avec des médulloblastomes. 
Découvertes récentes: 
Jusqu'à présent les patients étaient divisés en groupes à bas risque ou à haut risque sur la 
base de facteurs cliniques (âge, maladie résiduelle après chirurgie, dissémination dans le 
système nerveux central et l'histologie). Cette classification devrait être complétée par des 
facteurs pronostics moléculaires. Le profilage de l'expression des gènes a permis d'identifier 
six sous-groupes moléculaires de médulloblastomes. Le WNT sous-groupe montre une 
activation des gènes de la voie de signalisation WNT/wingless avec des mutations 
fréquentes du gène CNNTB1, une perte du chromosome 6 et une accumulation de /3-
catenine nucléaire. Ce sous-groupe est rencontré le plus souvent chez les enfants avec des 
médulloblastomes avec une histologie classique. Ils ont un bon pronostic. Une activation de 
la voie de signalisation du sanie hedgehog montre des mutations fréquentes des gènes 
PTCH et SUFU, une perte du 9q et une positivité pour GLl1 et SFRP1 et est rencontré plus 
fréquemment chez les enfants de moins de 3 ans et chez les adultes. Ce sous-groupe est 
souvent associé à une histologie de type desmoplastique. D'autre sous-groupes sont moins 
bien délimités et présentent des caractéristiques qui se chevauchent. Cependant une 
amplification MYC/MYCN, un gain du 17p et une histologie de type grandes 
cellules/anaplasique sont des facteurs de mauvais pronostic. 
Résumé: 
Des nouveaux sous-groupes moléculaires vont dorénavant aider à mieux adapter les 
traitements aux différents groupes de risque et permettront à développer de nouvelles 
thérapies ciblées. Des études prospectives et si possibles randomisées devraient ê.tre 
effectuées comprenant une stratification dans des sous-groupes moléculaires, afin 
d'identifier au mieux le meilleur traitement pour chaque groupe à risque. 
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Introduction 
Purpose of review 
Medulloblastomas are very rare in adults. Usual treatment consists of craniospinal 
radiation with or without chemotherapy. Current efforts focus on a better understanding 
of tumour biology, stratifying patients into risk groups and adapting treatment 
accordingly. This review discusses clinical and new molecular risk factors that will help 
to optimize treatment in adult medulloblastoma patients. 
Recent findings 
The clinical risk stratification should be complemented with new molecular prognostic 
markers. Gene-expression profiling has permitted identification of four to six molecular 
medulloblastoma subgroups. The WNT subgroup shows overexpression of genes of 
the WNT/wingless signalling pathway with frequent mutations of the CNNTB1 gene, 
loss of chromosome 6 and accumulation of nuclear 13-catenin, and is most often seen in 
children with medulloblastomas of classical histology. This variant has a good 
prognosis. Activation of the sonic hedgehog pathway with frequent mutations of the 
PTCH and SUFU genes, loss of 9q, and positivity for GLl1 and SFRP1 is more frequent 
in children less than 3 years old and in adults, commonly associated with desmoplastic 
histology. Other subgroups are not so well defined and have overlapping 
characteristics, but MYCIMYCN amplification, 17q gain and, large cell/anaplastic 
histology are factors of poor prognosis. 
Summary 
New molecular subgroups will help tailor treatment and further develop new targeted 
therapies. Prospective and ideal!y randomized trials should be performed in adults, 
including risk stratification by molecular markers, to identify optimal treatment for each 
risk group. 
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Embryonal tumours [medulloblastomas, primitive neuro-
ectodermal tumours (PNETs) and atypical teratoid/ 
rhabdoid tumours] are the most frequent primary brain 
tumours in children between 0 and 4 years. Medullo-
blastomas account for 13% of ail brain tumours in 
children from 0 to 14 years, 4% in children between 
15 and 19 years and 2% in young adults between 20 and 
34 years. In adults (defined as age > 18 years), medullo-
blastoma is a very rare tumour with a slight male predo-
minance (male-female ratio of 1.28) [1]. Five subtypes 
of medulloblastomas can be distinguished by histology: 
classical histology, desmoplastic/nodular medulloblas-
toma, medulloblastoma with extensive nodularity, ana-
plastie medulloblastoma and large cell medulloblastoma 
[2]. The extei;isive nodularity and anaplastie variants 
were only recently introduced in the Fourth Edition 
(2007) of the WHO classification [2]. The large cell 
and the anaplastie variants have a considerable cytolo-
gical overlap, so that in studies often a combined large 
cell/anaplastic category with poor prognosis has been 
used. The medulloblastoma with extensive nodularity 
is closely related to the desmoplastic/nodular variant and 
shares a more favourable outcome [3]. 
Because of the typical location in the posterior fossa, 
patients often present with symptoms of increased intra-
cranial pressure, hydrocephalus and/or cerebellar signs. 
Medulloblastomas have the particularity of early disse-
mination to the cranial and/or spinal subarachnoid space. 
In more advanced disease, extraneural metastases to the 
bone marrow, bone, lung (especially in children) and-liver 
may be present. 
1350-7540 © 2011 Wallers Kluwer Health 1 Lippincott Williams & Wilkins 001:10.1097 /WCO.Ob013e32834cd4b1 
The standard therapy includes local surgery followed by 
craniospinal radiation therapy with or without chemo-
therapy. 
Understanding prognosis and prognostic factors is crucial 
in order to decide on treatment strategy and intensity. 
Clinical prognostic factors have recently been comple-
mented by rapidly increasing molecular knowledge. 
Clinical prognostic factors 
Age, extent of residual disease after surgery, dissemina-
tion within the central nervous system and histology are 
clinical prognostic factors; however, their relative import-
ance and value varies between children and adults. 
Children 
Severa! hundreds of children have been included in 
prospective randomized trials that can now be tailored 
according to reliable risk factors. Extent of disease and 
resection status have been shown as important factors 
for survival. The commonly used Chang classification 
(Table 1) established already in 1969 distinguished 
tumour size and local invasiveness [4]. However, the 
T-stage has not been shown to be of prognostic value 
(5,6] and is thüs often no more reported. In patients with 
localized disease (MO) at diagnosis, the presence of 
residual tumour after surgery of more than 1.5 cm2 has 
been identified as an independent prognostic factor in 
several studies (5, 7,8], even if in other studies residual 
tumour appeared not to influence prognosis (9-12]. 
Possibly, these different results are dependent on the 
subsequently administered local and systemic treatment 
and may only be important in IVlO disease when less 
aggressive therapy is to be given. 
Patients are also grouped into high and low risk, based on 
presence or absence of disease dissemination (M-stage) at 
diagnosis, with Ml-M4 considered high-risk patients 
[5,6,11,13]. Patients with MO disease and less than 
1.5 cm2 residual disease should be considered as low risk 
or standard risk. Whether microscopie Ml disease 
(tumour cells in cerebrospinal fluid at least 14 days after 
surgery) has a true prognostic value is matter of debate. 
Table 1 Chang classification 
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11 Clinical prognostic factors such as stage and dis-
semination of disease (MO vs. Ml-4), extent of 
resection (controversial in adults) and histology 
should be completed by molecular prognostic fac-
tors. 
e Molecular subgroups can be identified by immuno-
histochemistry: CTNNB 1 expression for WNT 
subgroup, SFRPl for SHH subgroup, KCNAl for 
subgroup D and NPR3 for subgroup C, the latter 
existing only in children. 
• SHH-activated medulloblastomas are the most fre-
quent subtype in adults; the inhibition of SHH 
pathway by GDC-0449 has been suggested as a 
promising strategy in this subgroup. 
11 WNT subgroup has an excellent prognosis in chil-
dren, but not in adults. 
Severa! studies show a trend to inferior outcome without a 
statistically significant difference compared to MO disease 
(5,10,14]. Packer et al. [15] proposed an intermediate-risk 
group for Ml patients. Incomplete staging (9,16] and major 
deviations from the complex standard radiotherapy proto-
col [16, 17] were also adverse prognostic factors, whereas 
reducing dose of chemotherapy after occurrence of toxicity 
seemed not to have an impact on outcome [9]. 
Children younger than 3 years of age have often a more 
aggressive disease and a poor outcome. They may already 
present with more advanced and disseminated disease, 
allowing less often for complete resection and, because of 
the concern of treatment-induced neurotoxicity, receive 
less or no radiotherapy (18]. In two multicenter protocols 
by the German Paediatric Cancer Society (HIT-SKK'87 
and HIT-SKK'92), male sex and classical histology were 
associated with adverse outcome (19], whereas desmo-
plastic and extensive nodularity histology have an excel-
lent prognosis. 
Adults 
Controlled trials have never been performed in adults 
because of the rarity of the disease, and most data stem 
from retrospective analyses or prospective series collected 
T1 Tumour less than 3 cm in diameter and limited to the midline position in the vermis, the roof of the fourth ventricle, 
and less frequently to the cerebellar hemispheres 
î2 
T3a 
T3b 
T4 
Mo 
M1 
M2 
M3 
M4 
Tumour more than 3 cm in diameter, further invading one adjacent structure or partially filling the fourth ventricle 
Tumour further invading two adjacent structures or completely filling the fourth ventricle with extension into the 
aqueduc! of Silvius, foramen of Magendie, or foramen of Luschka, thus producing marked hydrocephalus 
Tumour arising from the floor of the fourth ventricle or brainstem and filling the fourth ventricle 
Tumour further spreading through the aqueduc! of Silvius to involve the third ventricle or midbrain, or tumour extending 
to the upper' cervical spinal cord 
No evidence of gross subarachnoid or hematogenous metastases 
Microscopie tumour cells in cerebrospinal fluid 
Gross nodular seeding demonstrated in cerebellar, cerebral, subarachnoid space or in the third or in the lateral ventricles 
Gross nodular seeding in spinal subarachnoid space 
Extraneural metastasis 
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over a long observation period of up to 20-30 years. 
Diagnostic tools, treatment techniques and therapeutic 
choices will have evolved over this time, adding to the 
heterogeneity [20-24]. 
An influence of age on prognosis in adults is not well 
established. In the Surveillance, Epidemiology, and End 
Results (SEER) database evaluating 454 adult patients 
with medulloblastoma, age of 18-20 years has been 
found to be a favourable prognostic factor in comparison 
to age aider than 20 years [20]. A similar finding was 
reported by Herrlinger et al. [21], who found age Jess than 
25 years is a strong prognostic factor for longer relapse-
free survival. In contrast, Menon et al. [25] compared the 
outcome of 18 adults and 79 children treated at a single 
institution and reported that adults fared better than 
children. Other studies did not find differences in out-
come solely based on age [22,26]. 
In most studies sex did not have any prognostic value 
[20,24-27], except for one study which showed that 
women fare better than men, similarly to observations 
in children [22]. 
The extent of disease and resection status have repeat-
edly been shown as important factors for survival 
[20,22,28,29,30",31]. A retrospective analysis on 253 
patients demonstrated a significant correlation of survival 
with metastasis, postsurgical performance status, brain-
stem involvement, involvement of the fourth ventricle, as 
well as radiation dose delivered to the spine and to the 
posterior cerebral fossa [30°]. Brainstem involvement and 
fourth ventricle invasion have been identified to predict 
poorer outcome [21,25,30°,32,33] and were often corre-
lated with extent of surgery [25,27,30°]. Gross total 
resection could only be identified in three studies as a 
prognostic factor [23,27,28]. However, before the wide-
spread availability of MRI, T-stage and resection status 
were subjectively determined by the surgeon only. 
Histological subtype has been reported to affect out-
come. In adults, desmoplastic histology is observed in 
15-40% [20,22-24,32], whereas large cell/anaplastic 
histology is very rare [20]. Carrie et al. [32] showed a 
significant improvement of event-free survival for des-
moplastic histology, and Herrlinger et al. [21) a trend for 
improved relapse-free survival. 
Until now, only one prospective trial in adults has been 
performed using clinical risk stratification. Initial results 
on 36 patients were reported in 2003 and updated with a 
longer follow-up in 2007 and expanded to 95 patients in 
2010 [29,33,34° 0 ). Thirty low-risk patients (Tl, T2, T3a, 
MO, with a residual disease <1.5 cm2) were treated with 
craniospinal irradiation alone (36 Gy+ boost of 18.8 Gy 
on tumour bed), whereas 65 patients with high-risk 
disease (T3b-T4, or postoperative residual tumour, or 
M positive) received platinum-based chemotherapy (cis-
platin 25 mg/m2/daily day 1-4, etoposide 40 mg/ m2/daily 
day 1-4, cyclophosphamide 1000 mg/m2 on day 4, every 
4 weeks) before and after radiotherapy. Survival at 5 and 
10 years were statistically different in low-risk (92 and 
65%) and high-risk patients (58 and 45%) and was sig-
nificantly inftuenced by the M status (47 and 29% in MO 
and M positive, respectively). Residual disease had no 
prognostic value [34° 0 ]. Late relapses after 5 years were 
common in al! risk groups and particularly important in 
the low-risk group. In the 36 patients published in 2003, 
there was a statistically significant difference in the 
outcome between low-risk and high-risk patients [29). 
Interestingly, with long-term follow-up this difference 
disappeared because of la te relapses in low-risk patients, 
suggesting that in low-risk patients chemotherapy may be 
of value and should be further investigated [33). 
Clinical differences between adults and children 
Overall, clinical prognostic factors appear comparable 
between adults and children, and patients can be separ-
ated into lower and higher risk for relapse. The more 
limited availability of solid data in adults however 
requires caution in interpretation and conclusions. Histo-
logical subtype is age-dependent, with desmoplastic 
histology being more frequent in adults [35). Lateral 
localization and hemisphere involvement is also more 
frequently observed [22,27,30°]. 
Comparing overall survival between children and adults, 
there seems to be no difference [29,36). However, late 
relapses are rare in children, but common in adults 5 and 
even 10 years after treatment. Up to 20% of patients 
relapse after 5 years [22,27). Extracranial metastases are 
fewer in adults than in children and if present are more 
often to the bone and Jung, whereas in children the site is 
preferentially to the liver [35). 
Molecular prognostic factors 
Accurate tumour classification and improved outcome 
prediction independent of clinical factors by gene-
expression profiling was already shown almost a decade 
ago [37,38]. In recent years, progress in biology and 
molecular analyses allows for better understanding of 
tumourigenesis and identification of distinct molecular 
subtypes that should ultimately allow for tailored 
treatment strategies. 
Children 
Numerous putative molecular factors have been ident-
ified almost exclusively in children. Prognostic markers 
that have been validated in larger cohorts are nucleopo-
sitivity for 13-catenin [39] and TrkC overexpression 
[38,40,41], bath indicating a more favourable prognosis, 
and ErB2 overexpression [42,43], isolated 17p Joss [42,44] 
or 17q gain [45] and MYCC/Jl;JYCN amplification [40,44, 
46,4 7], associated with a worse survival. Recently, 
upregulation of the LASPI gene located on chromosome 
17q has been associated with metastatic dissemination 
and poor outcome; in-vitro experiments suggest a raie of 
LASPl for cell adhesion, proliferation and migration [48]. 
Nuclear accumulation of [3-catenin, which is encoded by 
the CNNTBI gene, activated by the WNT/Wingless path-
way (WNT), has been found in 27of109 (25%) of children 
treated within the PNET3 trial of the International 
Society for Paediatric Oncology (SIOP)/United Kingdom 
Children's Cancer Study Group (UKCCSG). [3-Catenin 
nucleopositive medulloblastomas showed a significantly 
better overall survival than children with tumours that 
showed membranous/cytoplasmic immunoreactivity or no 
immunoreactivity [39]. The same study showed also that 
there is a good correlation with mutations in CTNNBI 
that were found exclusively in patients with positive 
nuclear [3-catenin immunoreactivity. 
La ter, Ellison et al. [ 49] demonstrated retrospectively the 
utility and feasibility of integrating molecular predictors 
in daily practice on 207 paraffin-embedded samples from 
the SIOP PNET3 trial. Nuclear immunoreactivity of 
[3-catenin, CTNBBI mutation and monosomy 6 as surro-
gates for Wnt pathway activation were associated with 
excellent prognosis, whereas MYC amplification was 
indicative of a very poor outcome. In their mode! of risk 
stratification, low-risk is defined as absence of metastases 
at diagnosis, classic histology and [3-catenin nucleoposi-
tivity; high-risk patients had either metastatic disease, 
either large cell/anaplastic histology or MYC amplifica-
tion [49,50]. Samples from the prospective randomized 
multicenter trial HIT'91 were analysed for DNA ampli-
fication of c-myc and N-myc, and mRNA expression of 
c-myc and trkC. c-myc and trkC were identified as 
independent prognostic factors [40]. Combination of 
these two risk factors permitted description of three risk 
groups. High trkC (> 1 x human cerebellum) and low 
c-myc (~ 1 x human cerebellum) identified eight children 
with favourable prognosis and 100% event-free survival 
(EFS) at 7 years; two of these children were metastatic at 
diagnosis. Law trkC and high c-myc were found in the 
poor prognosis group of 15 children; EFS was 33% at 
7 years. Ten of these fifteen children were metastatic at 
diagnosis. The remaining 78 patients had an intermediate 
· prognosis with an EFS of 65% at 7 years. Molecular 
markers were superior to clinical factors in outcome 
prediction [40]. 
By gene-expression profiling, four molecular subtypes 
were first described by Thompson et al. [51]. Specific 
mutations of genes associated with the Wnt (CTNNBI) 
or the sanie hedgehog pathway (PTCH; SUFU) were 
Medulloblastomas in adults Nay Fellay et al. 629 
subsequently identified and may allow for easier imple-
mentation of molecular markers in daily clinical practice. 
Cho et al. [52° 0 ] described six molecular subgroups when 
analysing 194 medulloblastoma samples by gene-expres-
sion profiling. On the basis of these data and clinical 
factors, they then proposed a nomogram indicating the 
relative prognostic value of a number of chromosomal 
aberrations or gene mutations [53]. Similarly, Northcott 
et al. [54 °0 ] reported on unsupervised gene-expression 
profiling of 103 primary medulloblastoma cases. They 
found four distinct subgroups of nonoverlapping gene 
signatures. Subsequent analysis by immunohistochemis-
try for DKKl (Wnt pathway), SFRPl (sanie hedgehog), 
NPR3 (natrionatriuretic peptide receptor) and KCNAl 
(potassium voltage-gated channel) allowed classification 
of tumour samples reliably into each molecular subgroup. 
Ali these studies (Table 2) consistently report an excel-
lent and distinct outcome for patients with Wnt pathway 
activation, a good prognosis when hedgehog is activated 
and a poor outcome with cMYC activation. The Wnt 
activation is also frequently associated with monosomy 
6 [54° 0 ] and classical histology, and was observed in ail 
(paediatric) age groups. The SHH subgroup is charac-
terized by 9q Joss and PTCHl mutation, and desmoplas-
tic histology, and most often occurs in children younger 
than 3 years and in adolescents and adults [51,52° 0 , 
54° 0 ,55]. 
Adults 
Ali of the discussed studies analysed mainly sampi es from 
paediatric medulloblastomas. Two recent studies specifi-
cally focussed on adults. The first analysed 34 medullo-
bastoma samples by comparative genomic hybridization 
[56°]. DNA copy number aberrations correlating with 
outcome were subsequently validated in a large inde-
pendent dataset of bath adult and paediatric patients. ln 
adults, bath type and frequency of genetic aberrations 
were distinct from paediatric samples. Furthermore, the 
negative prognostic value of CDK6 amplification, lOq Joss 
and 17 q gain were stronger than any of the known clinical 
prognostic factors. The authors propose to classify the 
patients based on their cytogenetic profile: high-risk 
group of bath lOq Joss and l 7q gain (estimated 5-year 
survival 0%); intermediate risk group of either lOq Joss or 
17 q gain ( estimated 5-year survival 44% ); and fin a li y a 
low-risk group with neither lOq Joss nor 17q gain (5-year 
survival 92%). Prospective validation is warranted. 
In a second study by the same group of investigators, 
gene-expression profiles of 28 adult medulloblastomas 
were analysed by unsupervised hierarchical clustering 
[57° 0 ]. Three different molecular subgroups were ident-
ified: Wnt/wingless pathway. activated genes (WNT), 
sanie hedgehog activated genes (SHH) and non-WNT/ 
SHH tumours that show a great concordance with the 
genetic profile of the previously described Northcott 
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subgroup D [54° 0 ,57""] (Table 2). Genetie loss on 6q, a 
hallmark of the prognostically favourable WNT tumours, 
was also identified in three early progressing patients 
without WNT activation. Adult WNT and subgroup D 
tumours have worse prognosis than in children. 
These three distinct molecular subsets were confirmed 
by immunostaining in an independent cohort of 103 adult 
medulloblastomas; each sample stained exclusively only 
for one of the three markers and none stained for NPR3 
(subtype C) [57" 0 ]. SSH subtype had a prevalence of 60% 
(SFRPl), subtype D 25% (KCNAl) and WNT subtype 
(CTNNBl) 15% .. Adult WNT and subgroup D tumours 
have worse prognosis than their paediatric counterparts 
[57°"]. 
Molecular differences between children and adults 
Adult medulloblastomas have a different genetic profile 
from those in children. lt is probable that clinical differ-
ences seen between children and adults are a con-
sequence of a distinct distribution of the different 
molecular subtypes over age. The SHH subtype has a 
higher incidence in adults, which can explain the clinical 
differences as the higher incidence of hemispheric local-
ization in adults and the predominant desmoplastic 
histology [35,57° 0 ]. 
Medulloblastoma was thought to arise from stem cells in 
the cerebellum, a developmental process that requires 
maturation, differentiation and migration. Recent work 
suggests that the subtype of Wnt pathway activated 
medulloblastoma may arise outside the cerebellum from 
cells of the dorsal brainstem and may th us explain in part 
the distinct natural history and prognosis [58]. 
Conclusion 
Molecular characterization allows nowadays accurate and 
reproducible identification of different subtypes of 
medulloblastoma, with improved prognostic value in 
children and adults. Therapeutic decisions and definition 
of treatment were until recently solely based on clinical 
factors. In paediatric low-risk patients, current strategies 
aim at reducing treatment intensity in order to lower 
acute and late toxicity. When chemotherapy bas been 
added to radiation therapy, the dose of the craniospinal 
irradiation could safely be reduced in low-risk patients 
[16,59], whereas treatment intensification and high-dose 
chemotherapy added to radiotherapy suggests improved 
outcome in children with high-risk disease [9]. Centre 
expertise and quality of radiotherapy have been shown to 
be of significant prognostic value, thus treatment should 
be delivered or planning reviewed by a reference centre. 
New trials should aim at validating these molecular 
signatures, and risk-adapted classification should allow 
optimization of treatment and improvement in outcome 
with current or future treatment strategies [60]. In adults, a 
distinct risk stratification should be further developed and 
validated [57" 0 ]. For the WNT subtype with a more 
favourable outcome, treatment intensity may possibly 
be reduced. On the other hand, cMYC-amplified tumours 
should receive more intensified treatment even when not 
metastatic. Recognition of the importance of the hedgehog 
pathway has already led to investigation of specifically 
targeted therapies. A recent report on a 26-year-old patient 
with a refractory medulloblastoma being treated with the 
hedgehog pathway inhibitor GDC-0449 showed impress-
ive tumour regression and improvements of symptoms 
[61° 0 ]. This agent is now being further investigated and 
three trials are open for accrual in adults and children. 
Molecular characterization may also allow better classifi-
cation of the rare and ill-defined PNETs. In a duit medul-
loblastomas, there is an urgent need for prospective and 
possibly randomized trials. Investigations need to include 
tissue collection in order to characterize molecular profiles 
and develop adapted treatment strategies. 
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